"shaboecrazy" as nuts as "wallyomoron!" 612k insider buying? Dah and Dah!!
Show us where there has been 612k in insider buying in 2013. Come on - show us the names and the total.
When a company gives options away, that is NOT insider buying. Shallcross was GIVEN 600k options struck at $.51 that vest over 4 years. Shallcross did NOT buy a SINGLE share of stock. He was GIVEN options.
Do you have any idea what you are reading and what you are trying to talk about? I guess not. How can you be in the market when you do not understand the most basic financial concepts?
There has NOT been 612k in insider buying during 2013. Get it? No I guess you don't.
Stroke is an enormous opportunity. Several regenerative medicine companies, including Athersys (ATHX), Cytomedix (CMXI.OB), and Neuralstem (CUR) are pioneering cell therapy for the treatment of stroke. Investors know the minefield of drug development that has been in Phase 2 and Phase 3 in stroke over the past decade for small molecules. Cell therapy, offering multiple mechanisms of action and multiple pathways to treat the disease yields hope. But MANF, a naturally occurring biologic, is equally as intriguing.
According to the CDC, there are an estimated 800,000 Americans that suffer a stroke each year. Approximately 90% of these are ischemic events, and 20% die from the event. The only approved treatment is Activase, a tissue plasminogen activator (tPA) with significant limitations for use. In fact, only around 2% of stroke patients qualify for tPA treatment. That leaves an estimated 575,000 Americans that could benefit from a new treatment paradigm.